DNAprint Genomics (DNAG)

[frogdreaming]

What are the ramifications of the Retinome announcement in regard to one of the historical topics of DNAP? Specifically the option agreement.

The option was granted to Orchid some years ago in exchange for some consideration (cash, machinery, I'm don't remember). It allowed Orchid to have the exclusive rights to DNAP's first product developed entirely in house. The option was for a period of six months after the presentation of the completed product.

Since that time the option has been reported to be tranfered from Orchid to Beckham. It has been suggested that the option period has run out, although no products have been introduced. (Ancestry and DNAWitness are exempt due to the outside collaboration of Dr Shriver).

Retinome was the expected 'first product' and although it has arrived considerably later than first envisioned it is still the 'first'.

DNAP has evidently combined Retinome into the DNAWitness suite of products for the benefit of marketing, but it is a stand alone product that has many applications outside of the forensic space.

Does Beckham still have the option?
The option allows them to match any offer from a second party, will this help to establish a 'value' for the product?
Will DNAP be limited to the forensic world in order to market it themselves and to prevent such a matching offer?
Is Beckham even interested?

Many questions..

regards,
frog